Cited by 69

Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo

Leucci, E, Zriwil, A, Gregersen, L H, Jensen, K T, Obad, S, Bellan, C, Leoncini, L, Kauppinen, S +1 more·2012·Oncogene

Abstract

MicroRNAs are important regulators of gene expression in normal development and disease. miR-9 is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, breast cancer and Hodgkin lymphoma (HL). Here we demonstrated a relevance for miR-9 in HL pathogenesis and identified two new targets Dicer1 and HuR. HL is characterized by a massive infiltration of immune cells and fibroblasts in the tumour, whereas malignant cells represent only 1% of the tumour mass. These infiltrates provide important survival and growth signals to the tumour cells, and several lines of evidence indicate that they are essential for the persistence of HL. We show that inhibition of miR-9 leads to derepression of DICER and HuR, which in turn results in a decrease in cytokine production by HL cells followed by an impaired ability to attract normal inflammatory cells. Finally, inhibition of miR-9 by a systemically delivered antimiR-9 in a xenograft model of HL increases the protein levels of HuR and DICER1 and results in decreased tumour outgrowth, confirming that miR-9 actively participates in HL pathogenesis and points to miR-9 as a potential therapeutic target.

Integrity signals

Registry

Crossref · 10.1038/onc.2012.15

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miR-9-3p was 64-fold higher in the cancer-derived cells.

    “miR-9-3p, 64-fold higher in the cancer-derived cells, has been previously reported as elevated in Hodgkin's lymphoma (Leucci et al. 2012) but not in these three cell types.”

    From Toward the human cellular microRNAome (2017) · cites this paper as Leucci et al. 2012

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Leucci, E., Zriwil, A., Gregersen, L. H., Jensen, K. T., Obad, S., Bellan, C., Leoncini, L., Kauppinen, S., & Lund, A. H.
Venue
Oncogene
Published
2012-02-06
Volume
31
Issue
49
Pages
5081-5089
ISSN
  • 0950-9232
  • 1476-5594
Cited by
69
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review